Chronic HCV Infection of Genotype 1, 4, 5, or 6
HCV RNA > 103 IU/mL at screening
18 years of age or older
Diagnosis of chronic HCV infection, defined as positive HCV antibody or HCV RNA more than 6 months prior to screening OR an assessment of fibrosis F2 or greater prior to screening.
NYHA Class III: Subjects with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain.
NYHA Class IV: Patient with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.
ejection fraction = 30%
hospitalized for heart failure in last 12 months
ILD criteria: diagnosis of interstitial lung disease with chronic supplemental oxygen requirement at rest and/or with exertion.
Forced expiratory volume (FEV1)< 30% predicted
OR any FEV1 with chronic supplemental oxygen requirement at rest and/or with exertion
OR any FEV1 with chronic hypercapnia (baseline partial pressure of arterial carbon dioxide [PaCO2] > 45)

NCT02858180_inc_T1
Condition
Chronic HCV Infection
NCT02858180_inc_T2
Qualifier
Genotype 1
NCT02858180_inc_T3
Qualifier
Genotype 4
NCT02858180_inc_T4
Qualifier
Genotype 5
NCT02858180_inc_T5
Qualifier
Genotype 6
NCT02858180_inc_T6
Scope
Genotype 1, 4, 5, or 6
NCT02858180_inc_T7
Measurement
HCV RNA
NCT02858180_inc_T8
Value
> 103 IU/mL
NCT02858180_inc_T9
Temporal
at screening
NCT02858180_inc_T10
Reference_point
screening
NCT02858180_inc_T11
Person
age
NCT02858180_inc_T12
Value
der
D  years 
NCT02858180_inc_T13
Condition
chronic HCV infection
NCT02858180_inc_T14
Measurement
HCV antibody
NCT02858180_inc_T15
Value
positive
NCT02858180_inc_T16
Measurement
HCV RNA
NCT02858180_inc_T17
Temporal
more than 6 months prior to screening
NCT02858180_inc_T18
Reference_point
screening
NCT02858180_inc_T19
Measurement
assessment of fibrosis
NCT02858180_inc_T20
Value
F2 or greater
NCT02858180_inc_T21
Temporal
prior to screening
NCT02858180_inc_T22
Reference_point
screening
NCT02858180_inc_T23
Scope
positive HCV antibody or HCV RNA more than 6 months prior to screening
NCT02858180_inc_T24
Measurement
NYHA
NCT02858180_inc_T25
Value
Class III
NCT02858180_inc_T28
Measurement
NYHA
NCT02858180_inc_T29
Value
Class IV
NCT02858180_inc_T30
Measurement
ejection fraction
NCT02858180_inc_T31
Value
= 30%
NCT02858180_inc_T32
Observation
hospitalized
NCT02858180_inc_T33
Condition
heart failure
NCT02858180_inc_T34
Temporal
in last 12 months
NCT02858180_inc_T35
Measurement
ILD criteria
NCT02858180_inc_T36
Condition
interstitial lung disease
NCT02858180_inc_T37
Observation
chronic supplemental oxygen requirement
NCT02858180_inc_T38
Qualifier
at rest
NCT02858180_inc_T39
Qualifier
with exertion
NCT02858180_inc_T41
Scope
at rest and/or with exertion
NCT02858180_inc_T42
Measurement
Forced expiratory volume
NCT02858180_inc_T43
Measurement
FEV1
NCT02858180_inc_T44
Value
< 30% predicted
NCT02858180_inc_T46
Observation
chronic supplemental oxygen requirement
NCT02858180_inc_T47
Qualifier
at rest
NCT02858180_inc_T48
Qualifier
with exertion
NCT02858180_inc_T50
Scope
at rest and/or with exertion
NCT02858180_inc_T52
Condition
chronic hypercapnia
NCT02858180_inc_T53
Measurement
partial pressure of arterial carbon dioxide
NCT02858180_inc_T54
Measurement
PaCO2
NCT02858180_inc_T55
Value
> 45